*Department of Radiology, Gustave Roussy-Cancer Campus, Villejuif, France; †Université Paris-Sud XI, UFR Médecine Le Kremlin-Bicêtre, Le Kremlin Bicêtre, France; ‡Department of Radiology, Mayo Clinic and Mayo Medical School, Rochester, Minnesota; §Department of Radiological Sciences, Ronald Reagan UCLA Medical Center, Los Angeles, California; and ‖Department of Radiology, Karmanos Cancer Institute, Detroit, Michigan.
J Thorac Oncol. 2015 Oct;10(10):1468-74. doi: 10.1097/JTO.0000000000000632.
To assess the feasibility, safety and local tumor control of cryoablation for treatment of pulmonary metastases.
This Health Insurance Portability and Accountability Act (HIPAA) compliant, IRB-approved, multicenter, prospective, single arm study included 40 patients with 60 lung metastases treated during 48 cryoablation sessions, with currently a minimum of 12 months of follow-up. Patients were enrolled according to the following key inclusion criteria: 1 to 5 metastases from extrapulmonary cancers, with a maximal diameter of 3.5 cm. Local tumor control, disease-specific and overall survival rates were estimated using the Kaplan-Meier method. Complications and changes in physical function and quality of life were also evaluated using Karnofsky performance scale, Eastern Cooperative Oncology Group performance status classification, and Short Form-12 health survey.
Patients were 62.6 ± 13.3 years old (26-83). The most common primary cancers were colon (40%), kidney (23%), and sarcomas (8%). Mean size of metastases was 1.4 ± 0.7 cm (0.3-3.4), and metastases were bilateral in 20% of patients. Cryoablation was performed under general anesthesia (67%) or conscious sedation (33%). Local tumor control rates were 56 of 58 (96.6%) and 49 of 52 (94.2%) at 6 and 12 months, respectively. Patient's quality of life was unchanged over the follow-up period. One-year overall survival rate was 97.5%. The rate of pneumothorax requiring chest tube insertion was 18.8%. There were three Common Terminology Criteria for Adverse Events grade 3 procedural complications during the immediate follow-up period (pneumothorax requiring pleurodesis, noncardiac chest pain, and thrombosis of an arteriovenous fistula), with no grade 4 or 5 complications.
Cryoablation is a safe and effective treatment for pulmonary metastases with preserved quality of life following intervention.
评估冷冻消融治疗肺转移瘤的可行性、安全性和局部肿瘤控制情况。
本研究符合《健康保险流通与责任法案》(HIPAA)和机构审查委员会(IRB)的规定,为一项多中心、前瞻性、单臂研究,共纳入 40 例患者的 60 个肺转移灶,在 48 次冷冻消融过程中进行治疗,目前的随访时间至少为 12 个月。根据以下主要纳入标准招募患者:1 至 5 个来自肺外癌症的转移灶,最大直径为 3.5cm。采用 Kaplan-Meier 法估计局部肿瘤控制率、疾病特异性生存率和总生存率。还使用 Karnofsky 表现量表、东部合作肿瘤学组表现状态分类和简短形式 12 项健康调查评估并发症以及身体功能和生活质量的变化。
患者的年龄为 62.6±13.3 岁(26-83 岁)。最常见的原发癌为结肠癌(40%)、肾癌(23%)和肉瘤(8%)。转移灶的平均大小为 1.4±0.7cm(0.3-3.4cm),20%的患者为双侧转移灶。冷冻消融在全身麻醉(67%)或清醒镇静(33%)下进行。6 个月和 12 个月时,58 个目标病灶中有 56 个(96.6%)和 52 个(94.2%)达到局部肿瘤控制。患者的生活质量在随访期间保持不变。1 年总生存率为 97.5%。需要插入胸腔引流管的气胸发生率为 18.8%。在即时随访期间有 3 例常见不良事件术语标准 3 级手术并发症(需要胸膜固定术的气胸、非心源性胸痛和动静脉瘘血栓形成),无 4 级或 5 级并发症。
冷冻消融治疗肺转移瘤是一种安全有效的方法,可保留干预后的生活质量。